What is the appropriate management for a patient with an estimated glomerular filtration rate of 46 mL/min/1.73 m²?

Management of Patient with eGFR 46 mL/min/1.73 m²

This patient has Stage 3a chronic kidney disease and should be started on an SGLT2 inhibitor immediately, with consideration for additional therapies based on albuminuria status, diabetes, and cardiovascular comorbidities.

Primary Therapeutic Approach

SGLT2 Inhibitor Initiation

The cornerstone of management for this patient is initiating an SGLT2 inhibitor. According to the 2024 KDIGO guidelines, adults with eGFR 20-45 mL/min/1.73 m² should receive SGLT2i therapy 1. The strength of this recommendation varies based on albuminuria:

• Strong recommendation (1A): If urine ACR ≥200 mg/g or heart failure is present 1
• Moderate recommendation (2B): If urine ACR <200 mg/g 1

Critical caveat: The initial eGFR decline after SGLT2i initiation is expected, reversible, and should NOT prompt discontinuation 1. This hemodynamic effect reflects reduced glomerular hyperfiltration and is actually protective long-term.

RAS Inhibitor (ACEi or ARB)

If not already prescribed, add an ACE inhibitor or ARB. Continue RASi therapy even as eGFR falls below 30 mL/min/1.73 m² 1.

Key monitoring parameters:

• Accept up to 30% creatinine rise within 4 weeks of initiation 1
• Only reduce dose or discontinue for: symptomatic hypotension, uncontrolled hyperkalemia despite treatment, or uremic symptoms when eGFR <15 1
• Manage hyperkalemia with potassium-lowering measures rather than stopping RASi 1

Additional Therapies Based on Clinical Context

If Type 2 Diabetes Present

Triple therapy is the goal 1:

1. SGLT2i (as above)

2. RASi (as above)

3. Nonsteroidal MRA (finerenone): Add if eGFR >25 mL/min/1.73 m², normal potassium, and albuminuria >30 mg/g despite maximum tolerated RASi dose 1

   • Dose: 10 mg daily for eGFR 25-59 mL/min/1.73 m² 1
   • Only initiate if K+ ≤4.8 mmol/L 1
   • Monitor potassium at 1 month, then every 4 months 1

4. GLP-1 RA: If glycemic targets not met despite metformin and SGLT2i, add long-acting GLP-1 receptor agonist with proven cardiovascular benefits 1

Monitoring Strategy

The eGFR of 46 places this patient at increased risk for adverse outcomes. A 2026 study demonstrated that mGFR of 60 mL/min/1.73 m² (compared to 90) was associated with 21% higher mortality risk (HR 1.21,95% CI 1.14-1.28) and nearly 3-fold higher risk of kidney failure requiring replacement therapy 2. This underscores the importance of aggressive intervention at this stage.

Do not alter CKD monitoring frequency simply because SGLT2i is initiated 1. The reversible eGFR decrease is expected and not an indication to stop therapy.

Medication Dosing Considerations

Use race-free, body surface area-adjusted eGFR for all medication dosing decisions, not Cockcroft-Gault 3. The 2024 KDIGO guidelines endorse this approach for equitable and evidence-based prescribing.

Common Pitfalls to Avoid

1. Stopping SGLT2i due to initial eGFR dip: This hemodynamic effect is protective, not harmful 4
2. Discontinuing RASi for mild creatinine elevation: Accept up to 30% rise 1
3. Stopping RASi for hyperkalemia without attempting potassium management first: Use dietary modification, potassium binders, or diuretic adjustment 1
4. Failing to continue therapies as eGFR declines further: Both SGLT2i and RASi should continue even below eGFR 20-30 unless specific contraindications arise 1